<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156739</url>
  </required_header>
  <id_info>
    <org_study_id>2012-1157</org_study_id>
    <secondary_id>NCI-2014-02333</secondary_id>
    <secondary_id>2012-1157</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT02156739</nct_id>
  </id_info>
  <brief_title>Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions</brief_title>
  <official_title>Radiologic Detection and Characterization of Benign and Malignant Liver Lesions in Contrast-Enhanced MRI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies contrast-enhanced magnetic resonance imaging (MRI) in detecting
      nonmalignant and malignant liver lesions. Diagnostic procedures, such as MRI, may help find
      and diagnose nonmalignant and malignant liver lesions. Contrast agents, such as gadoxetate
      disodium and gadobutrol, may help doctors to see MRI images more clearly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare the specificity of contrast enhanced MRI using a liver specific agent Eovist
      (gadoxetate disodium) versus the combined use of Eovist and an intravascular-extracellular
      agent Gadavist (gadobutrol) for the radiologic detection and characterization of liver
      lesions via clinical stability and follow up imaging.

      OUTLINE:

      Patients receive gadoxetate disodium intravenously (IV) over 1 minute and undergo MRI.
      Patients then receive gadobutrol IV over 1 minute at the 20 minute mark during MRI.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2014</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specificity of combining gadoxetate disodium and gadobutrol in diagnosing tumor lesions radiologically using magnetic resonance imaging (MRI)</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summary statistics of sensitivity, specificity, true positives, true negatives, false positives, and false negatives will be provided for gadoxetate disodium and gadoxetate disodium + gadobutrol method. Accuracy, sensitivity, specificity, positive predictive value, and negative predictive value will be estimated along with corresponding 95% confidence intervals for the two methods. Comparison between the two methods will be made following method by Obuchowski. Other statistical analyses will be carried out as appropriate.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Liver and Intrahepatic Bile Duct Disorder</condition>
  <condition>Metastatic Malignant Neoplasm in the Liver</condition>
  <condition>Primary Malignant Liver Neoplasm</condition>
  <arm_group>
    <arm_group_label>Diagnostic (contrast-enhanced MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receives each of these over one minute. For the gadoxetate disodium, dynamic imaging is performed immediately and imaging is performed at 20 minutes. For the gadobutrol, dynamic imaging is performed immediately.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Contrast-enhanced Magnetic Resonance Imaging</intervention_name>
    <description>Undergo contrast-enhanced MRI</description>
    <arm_group_label>Diagnostic (contrast-enhanced MRI)</arm_group_label>
    <other_name>CONTRAST ENHANCED MRI</other_name>
    <other_name>Contrast-enhanced MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadobutrol</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (contrast-enhanced MRI)</arm_group_label>
    <other_name>BAY86-4875</other_name>
    <other_name>Gadavist</other_name>
    <other_name>Gadograf</other_name>
    <other_name>Gadovist</other_name>
    <other_name>Protovis</other_name>
    <other_name>ZK 135079</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadoxetate Disodium</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Diagnostic (contrast-enhanced MRI)</arm_group_label>
    <other_name>Eovist</other_name>
    <other_name>Gadolinium EOB DTPA</other_name>
    <other_name>Gadolinium Ethoxybenzyl Diethylenetriaminepentaacetic Acid</other_name>
    <other_name>Gadoxetic Acid Disodium</other_name>
    <other_name>Gd-(S)-EOB-DTPA</other_name>
    <other_name>Gd-EOB-DTPA</other_name>
    <other_name>Primovist</other_name>
    <other_name>ZK 139834</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the most recent abdominal magnetic resonance (MR) study obtained within
             3 months +/- 1 week

          -  Patients with renal function (estimated glomerular filtration rate [eGFR] &gt;= 30)

          -  Any disease type

        Exclusion Criteria:

          -  Pregnant women

          -  Patients with impaired renal function (eGFR &lt; 30)

          -  Patients with surgical implants and/or metallic foreign bodies non-compatible with the
             MR magnet

          -  Patients with contraindications to the use of intravenous contrast such as allergic
             type reactions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vikas Kundra</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vikas Kundra, MD, PHD</last_name>
    <phone>713-745-2702</phone>
    <email>vkundra@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vikas Kundra</last_name>
      <phone>713-745-2702</phone>
      <email>vkundra@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vikas Kundra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 3, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Bile Duct Diseases</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edetic Acid</mesh_term>
    <mesh_term>Pentetic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

